추가 적립 안내

제약업계 유일의 영문 가이드 북

영문 가이드 북으로 매년 제작되고 있는 '파마슈티컬스 인 코리아'는 국내 제약산업부터 의료계, 제도·정책, 연구·개발, 시장동향 등에 이르기까지 최신정보를 폭넓게 제공하고 있습니다. 2016년판의 경우 엄선된 주요 국내 제약기업 및 생명공학기업들의 개요를 소상하게 설명하기 위해 별도의 섹션을 마련 했습니다. 이와 함께 한국의약푸무출입협회(KPTA)의 전체 회원사 리스트도 수록되어 있습니다.

'파마슈티컬스 인 코리아'(Pharmaceuticals in Korea) 2016년판

- 제약업계 유일의 영문 가이드 북
- 국내 제약산업에 대해 포괄적이면서 최신의 정보 및 자료 수록
- 주요 국내 제약/생명공학기업들의 개요와 핵심제품 소개

약업신문은 2016년판 '파마슈티컬스 인 코리아(Pharmaceuticals in Korea)'를 발간 했습니다.
영문 가이드 북으로 매년 제작되고 있는 '파마슈티컬스 인 코리아'는 국내 제약산업부터 의료계, 제도·정책, 연구·개발, 시장동향 등에 이르기까지 최신정보를 폭넓게 제공하고 있습니다. 2016년판의 경우 엄선된 주요 국내 제약기업 및 생명공학기업들의 개요를 소상하게 설명하기 위해 별도의 섹션을 마련 했습니다.
이와 함께 한국의약푸무출입협회(KPTA)의 전체 회원사 리스트도 수록되어 있습니다.

CHAPTER 1. PHARMACEUTICAL & DISTRIBUTION INDUSTRY

PART 1: PHARMACEUTICAL INDUSTRY OVERIEW

1) PHARMACEUTICAL MARKET TREND | 10
A) DOMESTIC PHARMACEUTICAL MARKET SIZE | 10
B) ACTIVE PHARMACEUTICAL INGREDIENT/FINISHED DRUG MANUFACTURING PERFORMANCE | 12
C) OTC/ETC DRUG MANUFACTURING PERFORMANCE | 13
D) MANUFACTURING PERFORMANCE BY THERAPEUTIC CATEGORY | 13
E) FINISHED DRUG MANUFACTURING PERFORMANCE BY PHARMACEUTICAL COMPANY | 14
F) MANUFACTURING PERFORMANCE BY MAIN PRODUCTS | 16
G) DOMESTIC NEW DRUG MANUFACTURING PERFORMANCE | 17
H) INCREMENTALLY MODIFIED DRUG MANUFACTURING PERFORMANCE | 19
I) ORPHAN DRUG MANUFACTURING PERFORMANCE | 20
2) PHARMACEUTICAL APPROVALS | 22
A) 2014 PHARMACEUTICAL APPROVALS AND REGISTRATIONS | 22
B) 2014 NEW DRUG APPROVALS | 23
C) 2014 NEW DRUG APPROVALS BY THERAPEUTIC CATEGORY | 26
D) DOMESTIC NEW DRUG APPROVALS | 29
3) PHARMACEUTICAL IMPORT AND EXPORT | 33
A) 2014 PHARMACEUTICAL IMPORT AND EXPORT PERFORMANCE | 33
B) ANNUAL PHARMACEUTICAL IMPORT AND EXPORT PERFORMANCE | 34
C) 2014 PHARMACEUTICAL IMPORT AND EXPORT PERFORMANCE BY COUNTRY | 35
D) 2014 PHARMACEUTICAL IMPORT PERFORMANCE BY THERAPEUTIC CATEGORY | 37
E) 2014 PHARMACEUTICAL IIMPORT PERFORMANCE OF TOP COMPANIES AND PRODUCTS | 38
F) TECHNOLOGY EXPORT AND EXPORT DIVERSIFICATION | 40
G) DEPENDENCE LOW ON EXPORTS BUT HIGH ON DOMESTIC MARKET | 43
4) RESEARCH AND DEVELOPMENT | 46
A) OVERALL CONDITION OF R&D-BASED PHARMACEUTICAL COMPANIES | 46
B) NEW DRUG DEVELOPMENT REQUIRED 9.1 YEARS AND SPENT KRW 38 BILLION ON AVERAGE | 49
C) TREND OF LISTED PHARMACEUTICAL COMPANIES ENLARGING R&D EXPENSES | 51
D) "POLARIZATION" OF PHARMACEUTICAL COMAPNIES IN R&D | 53
E) INCREMENTALLY MODIFIED NEW DRUG DEVELOPMENT RESULTS | 55
F) TECHNOLOGY EXPORTS OF DOMESTIC LISTED PHARMACEUTICAL COMPANIES | 58
5) PHARMACEUTICAL ADVERTISING | 61
A) DIRECT-TO-CONSUMER PHARMACEUTICAL ADVERTISING | 61
B) TIGHTENED DELIBERATION OF OTC DRUGS DTC ADVERTISEMENT | 62
C) ADVERTISING EXPENSES OF LISTED PHARMACEUTICAL COMPANIES IN 2014 | 63
D) ADVERTISING EXPENSES OF MULTINATIONAL PHARMACEUTICAL COMPANIES IN 2014 | 65
6) MULTINATIONAL PHARMACEUTICAL COMAPNEIS ENTERED IN KOREA | 67
A) SALES AND PROFITS OF FOREIGN PHARMACEUTICAL COMAPNEIS IN 2014 | 67
B) ANNUAL SALES PER EMPLOYEE OF EACH FOREIGN PHARMACEUTICAL COMPANY | 68
C) FOREIGN PHARMACEUTICAL COMAPNIES SPENT 4.5% OF SALES IN ADVERTISING EXPENSES | 70
D) PATENT APPLICATIONS OF DOMESTIC PHARMACEUTICAL COMPANIES ACCOUNTING FOR 18% OF FOREIGN ONES | 71
7) PHARMACISTS AND PHARMACIES | 73
A) PHARMACIST LICENSE HOLDERS ACROSS THE NATION | 73
B) NARROWLY INCREASING NUMBER OF PHARMACIES | 75
C) DECREASING FREQUENCY OF UTILIZATION OF PHARMACIES | 77
D) ADOPTION OF PHARMACEUTICAL SALES SYSTEM AT THE OUTSIDE OF PHARMACIES | 78

PART 2: BIOINDUSTRY OVERVIEW
1) BIOINDUSTRIAL MARKET TREND | 80
A) BIOINDUSTRY INTRODUCTION | 80
B) MANUFACTURING SCALE OF DOMESTIC BIOINDUSTRY | 82
C) DEVELOPMENT TREND OF BIOSIMILARS | 87
2) BIOINDUSTRIAL PROMOTION | 89
A) BIOINDUSTRY POLICIES | 89
B) STRATEGY TO PROMOTE BIO-RELATED NEW INDUSTRIES | 89
C) FUTURE OF DOMESTIC BIOINDUSTRY | 91

PART 3: PHARMACEUTICAL DISTRIBUTION INDUSTRY
1) PRESENT STATE OF PHARMACEUTICAL DISTRIBUTION INDUSTRY | 93
A) INCREASING NUMBER OF PHARMACEUTICAL DISTRIBUTION COMPANIES SINCE NEW MILLENNIUM | 93
B) SUDDEN CHANGES OF PHARMACEUTICAL DISTRIBUTION ENVIRONMENT | 94
C) SECUREMENT OF REASONABLE PHARMACEUTICAL DISTRIBUTION COST | 97
2) BUSINESS PERFORMANCE OF PHARMACEUTICAL DISTRIBUTION COMPANIES | 98
A) THE RICH-GET-RICHER AND THE POOR-GET-POORER IN BUSINESS PERFORMANCE | 98
B) TOP 5% COMPANIES SUPPLYING 60% OF THE ENTIRE INDUSTRY | 102

PART 4: HEALTH FUNCTIONAL FOOD INDUSTRY
1) HEALTH FUNCTIONAL FOOD MARKET OVERVIEW | 104
A) ADOPTION OF GMP POLICY | 104
B) ENACTMENT OF THE HEALTH FUNCTIONAL FOOD ACT | 105
C) PRESENT STATE OF HEALTH FUNCTIONAL FOOD COMPANIES | 106
D) ENTRY TO KRW 1 TRILLION MARKET IN 2010 | 108
E) HEALTH FUNCTIONAL FOOD MANUFACTURING VOLUME OF KRW 1.5 TRILLION IN 2013 | 109
F) HEALTH FUNCTIONAL FOODS BY PRODUCT AND COMPANY | 110
G) HEALTH FUNCTIONAL FOOD IMPORT | 113
2) NEW TREND OF HEALTH FUNCTIONAL FOOD | 115
A) OVER 50% OF ADULTS EXPERIENCING IN PURCHASING HEALTH FUNCTIONAL FOODS | 115
B) SUPERMARKETS BECOMING THE KEY DISTRIBUTION CHANNEL FOR HEALTH FUNCTIONAL FOODS | 116
C) INCREASING CONSUMPTION OF HEALTH FUNCTIONAL FOODS AMONG YOUNG PEOPLE | 117
D) SAFETY TIGHTENING AND REGULATION RATIONALIZATION | 118

PART 5: MEDICAL EQUIPMENT INDUSTRY
1) MEDICAL EQUIPMENT MARKET OVERVIEW | 120
A) MEDICAL EQUIPMENT MANUFACTURING PERFORMANCE | 120
B) MEDICAL EQUIPMENT EXPORT OF USD 240 MILLION IN 2014 | 121
C) STRATEGY TO PROMOTE MEDICAL EQUIPMENT INDUSTRY | 123

CHAPTER 2. POLICY AND RELATED SYSTEM

PART 1: PHARMACEUTICAL INDUSTRY POLICY
1) BASIC DIRECTIN OF PHARMACEUTICAL POLICY | 126
A) "LIGHT AND SHADE" OF KOREAN PHARMACEUTICAL INDUSTRY | 126
B) ENACTMENT OF SPECIAL ACT TO SUPPORT PHARMACEUTICAL INDUSTRY | 129
C) ANNOUNCEMENT OF 'PHARMA KOREA 2020' VISION | 130
D) PROMOTION OF 12 GLOBAL PHARMACEUTICAL COMAPNIES BY 2020 | 131
E) SELECTION OF 'INNOVATIVE PHARMACEUTICAL COMPANIES' | 132
F) FIRST ESTABLISHMENT OF FUND SPECIALIZING IN PHARMACEUTICAL INDUSTRY | 134
2) KOREA-US FTA AND PHARMACEUTICAL SOVEREIGNTY PROTECTION | 135
A) ACTIVE NEGOTIATIONS OF KOREA-US FTA | 135
B) KOREA-US FTA SETTLEMENT AS A NEW TRADE RULES | 136
C) ENFORCEMENT OF 'PATENT-LINKAGE SYSTEM' | 137

PART 2: NATIONAL HEALTH INSURANCE
1) HEALTH INSURANCE SYSTEM OVERVIEW | 139
A) HEALTH INSURNACE ENROLLMENT | 140
B) HEALTH INSURANCE FEES AND BENEFITS | 141
C) MEDICAL INSTITUTIONS AND PERSONNEL | 145
D) HEALTH INSURANCE FINANCES | 147
E) EXPANDED HEALTH INSURANCE COVERAGE | 149
2) HEALTH INSURANCE PAYMENT SYSTEM | 150
A) FEE-FOR-SERVICE PAYMENT SYSTEM | 150
B) DIAGNOSIS-RELATED GROUP(DRG) PAYMENT SYSTEM ON 7 DISEASE GROUPS | 150
C) INSURANCE COVERAGE EXTENSION FOR SEVERE DISEASES | 151
3) DRUG PRICING POLICY OF NATIONAL HEALTH INSURANCE | 152
A) BACKGROUND OF DRUG PRICING POLICY REFORM | 152
B) POSITIVE LIST SYSTEM | 152
C) INCENTIVE SYSTEM FOR LOW-PRICE PURCHASE | 153
D) PACKAGE DURG PRICE REDUCTION SYSTEM | 154
E) USAGE-PRICE LINKAGE SYSTEM | 154
F) INCENTIVE SYSTEM FOR DRUG PRESCRIBING AND DISPENSING EXPENSE CUTS | 155
G) INCENTIVE SYSTEM FOR LOW-PRICE PURCHASE (MARKET-BASED ACTUAL TRANSACTION PRICE SYSTEM) | 155
H) ADOPTION OF RISK-SHARING SYSTEM | 156
I) INCENTIVE SYSTEM FOR LOW-PRICE GENERIC SUBSTITUTION | 156

PART 3: SPECIAL FEATURE
THE PRESENT AND FUTURE OF THE KOREAN PHARMACEUTICAL INDUSTRY
1) SOCIAL AND ECONOMIC CONTRIBUTION OF THE PHARMACEUTICAL INDUSTRY | 159
2) THE DOMESTIC PHARMACEUTICAL INDUSTRY’S R&D INVESTMENTS AND RESULTS | 166
3) R&D PIPELINES OF THE DOMESTIC PHARMACEUTICAL INDUSTRY | 171
4) FOREIGN EXPANSION OF THE DOMESTIC PHARMACEUTICAL INDUSTRY | 173
5) PROSPECT OF THE DOMESTIC PHARMACEUTICAL INDUSTRY | 174
6) CONCLUSION | 180

Chapter 3. Pharmaceutical Corporation Introduction

Ahngook Pharm. Co., Ltd. | 182
Boryung Pharmaceutical Co., Ltd. | 190
Chong Kun Dang Pharmaceutical Corp. | 200
CL Pharm Co., Ltd. | 216
DAE HWA Pharmaceutical Co., Ltd. | 218
Daewoong Pharmaceutical Co., Ltd. | 234
Dong Wha Pharmaceutical Co., Ltd. | 246
Enzychem Lifesciences Corporation | 276
Green Cross | 280
Hanlim Pharm. Co., Ltd. | 282
Hanmi Pharm. Co., Ltd. | 302
Hyundai Pharm. Co., Ltd. | 332
Ildong Pharmaceutical Co., Ltd. | 338
JW Pharmaceutical Corporation | 350
Kolmar Korea Co., Ltd. | 366
Korea United Pharm. Inc. (KUP) | 372
Myungmoon Pharmaceutical Co., Ltd. | 386
Samjin Pharm. Co., Ltd. | 408
Tai Guk Pharm. Co., Ltd. | 426
Countec Co., Ltd. | 434
PTK Co., Ltd. | 440
Kyungyon Exhibition Corporation| 450
Chapter 4. Korea Pharmaceutical Traders Association
Membership List
KPTA Member List | 458